Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Current
    • Residents & Fellows
    • Without Borders
    • Practice Buzz
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Current
    • Residents & Fellows
    • Without Borders
    • Practice Buzz
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub

Share

April 2015; 2 (2) Editor's CornerOpen Access

Identifying targets for diagnosis, prognosis, and treatment

Josep Dalmau
First published April 2, 2015, DOI: https://doi.org/10.1212/NXI.0000000000000087
Josep Dalmau
From the Catalan Institution of Research and Advanced Studies (ICREA) and Biomedical Research Institute August Pi i Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Identifying targets for diagnosis, prognosis, and treatment
Josep Dalmau
Neurol Neuroimmunol Neuroinflamm Apr 2015, 2 (2) e87; DOI: 10.1212/NXI.0000000000000087

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
605

Share

  • Article
  • Info & Disclosures
Loading

This issue of Neurology® Neuroimmunology & Neuroinflammation (N2) incorporates exciting studies on the biology of immunologic and inflammatory biomarkers and the importance of knowing the benefits and complications of targeted therapies. In addition, the issue includes several clinically relevant reports on viral and autoimmune encephalitis. The concept of precision medicine, recently re-enhanced by public media, is not new in clinical and basic research. An interesting example is the case presented by Euskirchen et al.1 of a patient with life-threatening brainstem neurohistiocytosis in the context of Erdheim-Chester disease and cutaneous Langerhans cell histiocytosis. Detection of a BRAF mutation in affected tissues led to the selection of a specific BRAF inhibitor (vemurafenib), resulting in a rapid clinical response. On the other hand, Kornberg et al.2 suggest that the use of targeted therapies in an inappropriate context, such as fingolimod and natalizumab in neuromyelitis optica (NMO) instead of multiple sclerosis (MS), carries the risk of disease exacerbation. The authors postulate that a combination of drug effects, including an increase of blood-brain barrier permeability allowing CNS entry of Th17 lymphocytes, was responsible for the clinical worsening in the case they present. In another report, Hillen et al.3 postulate that natalizumab may have contributed to fulminant liver failure related to hepatitis B infection in a patient receiving the drug for relapsing-remitting MS (RRMS). Svenningsson et al.4 show that rituximab, a drug used for both MS and NMO, rapidly distributes to the peripheral compartment following intrathecal administration. Ultra-low doses of intrathecal rituximab were sufficient to cause complete and prolonged depletion of B lymphocytes in both the CNS and systemic compartments, an observation with potential implications for other disorders, such as autoimmune encephalitis.

Three additional studies use immunologic cells or autoantibodies as biomarkers of disease or treatment outcome. In a study of children with a first episode of acquired demyelinating syndrome, Hacohen et al.5 found that the presence of myelin oligodendrocyte glycoprotein (MOG) antibodies at symptom onset predicted a non-MS disease course. These findings confirm previous studies indicating that patients with optic neuritis and MOG antibodies have a low probability of developing MS or NMO.6 De Raedt et al.7 describe that the detection of a high circulating natural killer (NK) cell count within the first hours after an acute ischemic stroke, followed by a drop in all lymphocyte subsets, identifies patients prone to develop infections, likely as a result of autonomic dysfunction with sympathetic overdrive. Elkins et al.8 investigated the relationship between CD56bright NK cells and disease activity in patients with RRMS treated with daclizumab high-yield process (DAC HYP). In this preliminary study, the authors found a statistically significant inverse relationship between CD56bright NK cell counts measured after DAC HYP and the number of new or enlarged T2-hyperintense lesions that developed between weeks 24 and 52 posttreatment. The findings, which need validation in prospective studies, suggest that CD56bright NK cell counts should be considered as a potential surrogate to understanding individual variation in the treatment response to DAC HYP.

A study by Bar-Or et al.9 provides Class II evidence that in normal subjects treated with teriflunomide (a drug used in RRMS that blocks pyrimidine synthesis), antibody titer responses to rabies vaccination are lower than with placebo but sufficient for seroprotection. The findings support the view that teriflunomide decreases autoaggressive immune responses in MS but does not limit the ability to mount primary adaptive humoral immune responses or alter delayed T-cell hypersensitivity. The work of Guptill et al.10 shows that patients with muscle-specific tyrosine kinase myasthenia gravis have higher plasma B cell–activating factor levels and lower percentages of B10 cells than healthy controls. The authors suggest that the reduction of regulatory B10 cells, which produce the anti-inflammatory cytokine interleukin (IL)-10, likely explains a previously reported increase of proinflammatory Th1 and Th17 responses, breaking down immune tolerance and resulting in the generation of autoreactive B cells.11 In another study, Moore et al.12 used human fetal and adult microglia to confirm that expression of the P2Y12 receptor (an ADP-responsive G protein–coupled receptor also expressed by platelets) is enhanced under alternatively activated (M2, IL-4, and IL-13) conditions, mediating cell migration and participating in acute proinflammatory responses toward danger-associated molecules that are released during CNS injury. The findings may provide a novel strategy for treating CNS inflammatory disorders.

In the fields of viral, paraneoplastic, or autoimmune encephalitis, 5 interesting articles are included in this issue. Marques et al.13 describe a challenging case of varicella-zoster encephalitis mimicking toxoplasmosis relapse; the clinical and MRI features suggesting hemorrhagic encephalitis with vasculopathy were important clues to the diagnosis, which was confirmed with CSF viral studies. Liba et al.14 describe a patient with Rasmussen encephalitis who dramatically responded to aggressive immunotherapy with steroids, cyclophosphamide, and mycophenolate mofetil; the short clinical follow-up suggests caution in the interpretation of this intriguing result. Probst et al.15 confirm that a novel cell-based assay expressing Delta/Notch-like epidermal growth factor-related receptor confers high sensitivity and specificity for determination of Tr antibodies, which usually occur in association with cerebellar degeneration and Hodgkin lymphoma. Körtvelyessy et al.16 provide the neuropathologic findings in the hippocampus and amygdala of a patient with autoimmune encephalitis and CASPR2 antibodies. Among moderate amounts of CD3+ and CD8+ T lymphocytes (without neuronophagic nodules) and small numbers of B cells and plasma cells, the authors found deposits of complement in a few neurons, suggesting a complement-mediated mechanism. The case is interesting because CASPR2 antibodies are usually IgG4, an isotype that does not fix complement. Finally, Simabukuro et al.17 report a case of recurrent thymoma and autoimmune encephalitis associated with cortical and subcortical fluid-attenuated inversion recovery MRI abnormalities and antibodies to both GABAA receptor and LGI1. The tumor expressed both autoantigens, and the patient had a remarkable recovery after tumor removal and immunotherapy. This case highlights the complexity of autoimmune encephalitis associated with several concurrent autoantibodies.

I hope you enjoy reading these articles and encourage you to submit your work to N2.

DISCLOSURE

J. Dalmau is the editor of Neurology: Neuroimmunology & Neuroinflammation; is on the editorial board for Neurology UpToDate; holds patents for and receives royalties from Ma2 autoantibody test and NMDA receptor autoantibody test; has patent applications for and receives royalties from GABA(B) receptor autoantibody test, GABA(A) receptor autoantibody test, DPPX autoantibody test, and IgLON5 autoantibody test; and received research support from Euroimmun, NIH, and Fondo de Investigaciones Sanitarias de la Seguridad Social (Instituto Carlos III, Spanish Government). Go to Neurology.org/nn for full disclosure forms.

Footnotes

  • Funding information and disclosures are provided at the end of the article. Go to Neurology.org/nn for full disclosure forms.

  • © 2015 American Academy of Neurology

This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

REFERENCES

  1. 1.↵
    1. Euskirchen P,
    2. Haroche J,
    3. Emile JF,
    4. Buchert R,
    5. Vandersee S,
    6. Meisel A
    . Complete remission of critical neurohistiocytosis by vemurafenib. Neurol Neuroimmunol Neuroinflamm 2015;2:e78. doi: 10.1212/NXI.0000000000000078.
    OpenUrl
  2. 2.↵
    1. Kornberg MD,
    2. Newsome SD
    . Unmasking and provoking severe disease activity in a patient with NMO spectrum disorder. Neurol Neuroimmunol Neuroinflamm 2015;2:e66. doi: 10.1212/NXI.0000000000000066.
    OpenUrl
  3. 3.↵
    1. Hillen ME,
    2. Cook SD,
    3. Samanta A,
    4. Grant E,
    5. Quinless JR,
    6. Rajasingham JK
    . Fatal acute liver failure with hepatitis B virus infection during natalizumab treatment in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2015;2:e72. doi: 10.1212/NXI.0000000000000072.
    OpenUrl
  4. 4.↵
    1. Svenningsson A,
    2. Bergman J,
    3. Dring A,
    4. et al
    . Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally. Neurol Neuroimmunol Neuroinflamm 2015;2:e79. doi: 10.1212/NXI.0000000000000079.
    OpenUrlPubMed
  5. 5.↵
    1. Hacohen Y,
    2. Absoud M,
    3. Deiva K,
    4. et al
    ; United Kingdom Childhood Inflammatory Demyelination (UK-CID) and French Kidbiosep Study Groups. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm 2015;2:e81. doi: 10.1212/NXI.0000000000000081.
    OpenUrl
  6. 6.↵
    1. Rostasy K,
    2. Mader S,
    3. Schanda K,
    4. et al
    . Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol 2012;69:752–756.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. De Raedt S,
    2. De Vos A,
    3. Van Binst AM,
    4. et al
    . High natural killer cell number might identify stroke patients at risk of developing infections. Neurol Neuroimmunol Neuroinflamm 2015;2:e71. doi: 10.1212/NXI.0000000000000071.
    OpenUrl
  8. 8.↵
    1. Elkins J,
    2. Sheridan J,
    3. Amaravadi L,
    4. et al
    . CD56bright natural killer cells and response to daclizumab HYP in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm 2015;2:e65. doi: 10.1212/NXI.0000000000000065.
    OpenUrl
  9. 9.↵
    1. Bar-Or A,
    2. Wiendl H,
    3. Miller B,
    4. et al
    . Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens. Neurol Neuroimmunol Neuroinflamm 2015;2:e70. doi: 10.1212/NXI.0000000000000070.
    OpenUrl
  10. 10.↵
    1. Guptill JT,
    2. Yi JS,
    3. Sanders DB,
    4. et al
    . Characterization of B cells in muscle-specific kinase antibody myasthenia gravis. Neurol Neuroimmunol Neuroinflamm 2015;2:e77. doi: 10.1212/NXI.0000000000000077.
    OpenUrl
  11. 11.↵
    1. Yi JS,
    2. Guidon A,
    3. Sparks S,
    4. et al
    . Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis. J Autoimmun 2014;52:130–138.
    OpenUrl
  12. 12.↵
    1. Moore CS,
    2. Ase A,
    3. Kinsara A,
    4. et al
    . P2Y12 expression and function in alternatively activated human microglia. Neurol Neuroimmunol Neuroinflamm 2015;2:e80. doi: 10.1212/NXI.0000000000000080.
    OpenUrl
  13. 13.↵
    1. Marques IB,
    2. Flanagan S,
    3. Noble H,
    4. Giovannoni G,
    5. Marta M
    . Varicella-zoster virus encephalitis mimicking toxoplasmosis relapse. Neurol Neuroimmunol Neuroinflamm 2015;2:e74. doi: 10.1212/NXI.0000000000000074.
    OpenUrl
  14. 14.↵
    1. Liba Z,
    2. Muthaffar O,
    3. Tang J,
    4. et al
    . Rasmussen encephalitis: response to early immunotherapy in a case of immune-mediated encephalitis. Neurol Neuroimmunol Neuroinflamm 2015;2:e69. doi: 10.1212/NXI.0000000000000069.
    OpenUrl
  15. 15.↵
    1. Probst C,
    2. Komorowski L,
    3. de Graaf E,
    4. et al
    . Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degeneration. Neurol Neuroimmunol Neuroinflamm 2015;2:e68. doi:10.1212/NXI.0000000000000068.
    OpenUrl
  16. 16.↵
    1. Körtvelyessy P,
    2. Bauer J,
    3. Stoppel CM,
    4. et al
    . Complement-associated neuronal loss in a patient with CASPR2 antibody–associated encephalitis. Neurol Neuroimmunol Neuroinflamm 2015;2:e75. doi: 10.1212/NXI.0000000000000075.
    OpenUrl
  17. 17.↵
    1. Simabukuro MM,
    2. Petit-Pedrol M,
    3. Castro LH,
    4. et al
    . GABAA receptor and LGI1 antibody encephalitis in a patient with thymoma. Neurol Neuroimmunol Neuroinflamm 2015;2:e73. doi: 10.1212/NXI.0000000000000073.
    OpenUrl

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Info & Disclosures

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Advertisement
Neurology - Neuroimmunology Neuroinflammation: 9 (4)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise